Gene Expression In Pregnancies Complicated by Preeclampsia
- Conditions
- Preeclampsia
- Registration Number
- NCT00919360
- Lead Sponsor
- University of Rochester
- Brief Summary
The purpose of this study is to figure out some of the differences in bodily function between women who have preeclampsia and those who do not.
* This may eventually lead to an understanding of its cause. At this time, there is no known way to prevent preeclampsia, and the cause is not known.
* The only treatment is delivery of the baby, even if it is premature, in order to decrease the risk to the mother.
- Detailed Description
* Preeclampsia is a pregnancy-related disorder that occurs in about 6% of all pregnancies.
* In its mild for, preeclampsia involves high blood pressure. More severe forms of preeclampsia can lead to more serious pregnancy complications.
* At this time, there is no known way to prevent preeclampsia, and the cause is not known. The only treatment is delivery of the baby, even if it is premature, in order to decrease the risk to the mother.
* The purpose of this study is to figure out some of the differences in bodily function between women who have preeclampsia and those who do not. This may eventually lead to an understanding of its cause.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- Female
- Target Recruitment
- 125
- Gravidas at 32-42 weeks gestation,who have preeclampsia as defined by Sibai et al, 1997.
- Control patients: Gravidas without history of hypertension of any kind, and matched to cases for parity, gestational age, labor status, maternal age, and race.
- Prior betamethasone administration, fetal growth restriction (<3%ile), prior chronic hypertension (nonpregnant or < 20 weeks gestation any pregnancy), chorioamnionitis, major fetal anomaly or chromosome abnormality, multiple gestation, and maternal diabetes (any class except diet-controlled gestational).
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Relative pattern of expression in cases and matched controls of a robust set of genes in the VEGF/sFLT mediated model for preeclampsia in the placenta and decidua 1- 2 years
- Secondary Outcome Measures
Name Time Method Using relative expression analysis in an embedded set of control subjects, determine whether common variables e.g. labor, parity independently influence expression of these genes of interest in the tissues studied 1 - 2 years Determine the population variance for each gene of interest 1 - 2 years From this expression pattern,determine the validity of 18s ribosomal subunit as an endogenous control in this tissue. 1- 2 years
Trial Locations
- Locations (1)
University of Rochester Medical Center
🇺🇸Rochester, New York, United States
University of Rochester Medical Center🇺🇸Rochester, New York, United States